3:22 PM
 | 
Nov 16, 2018
 |  BC Extra  |  Financial News

Alphamab Oncology raises more than $100M series A

Immuno-oncology company Alphamab Oncology (Cayman) raised over $100 million in a series A round to accelerate development of its biologics including lead product KN035. Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >